The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability
Vir Biotechnology (VIR) reported a significant swing to profitability in Q2 2026, with revenues reaching US$238.95 million and net income of US$80.08 million, replacing a prior net loss. This unexpected financial performance, driven partly by a collaboration with Astellas, alters the investment narrative by easing near-term funding concerns. However, the company still faces risks related to clinical trial outcomes and long-term development costs, which remain crucial factors for its future valuation and stock performance.
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability
Vir Biotechnology (VIR) reported a significant swing to quarterly profitability in Q2 2026, with revenue of US$238.95 million and net income of US$80.08 million, replacing previous losses. This shift is largely attributed to a collaboration with Astellas. While improving short-term funding optics, the company still faces risks related to pivotal trial outcomes and development costs, which could impact its long-term financial profile and fair value.
Vir Biotechnology Stock Price Forecast. Should You Buy VIR?
StockInvest.us rates Vir Biotechnology, Inc. (VIR) as a "Buy Candidate" with a technical score of 3.46, noting a 1.62% price gain on the last trading day and a 5.51% increase over two weeks. The analysis indicates mostly positive signals, including buy signals from short and long-term Moving Averages and a pivot bottom point. The stock is expected to trade within a wide horizontal trend between $8.77 and $10.61 over the next three months, with potential resistance at $9.54 and support at $9.16.
Vir Biotechnology Reports 96-Week Phase 2 Hepatitis Delta Data for Tobevibart and Elebsiran Combination
Vir Biotechnology announced complete 96-week Phase 2 SOLSTICE trial data for its combination therapy of tobevibart and elebsiran for chronic hepatitis delta virus (HDV) infection. The regimen demonstrated sustained virologic suppression in 100% of participants and improvements in liver function biomarkers, with no new safety signals. These results support the potential of multi-targeted functional cure strategies for HDV, which is the most severe form of chronic viral hepatitis.
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript
Vir Biotechnology (VIR) reported significant financial improvements in Q2 2026, with $1.01 billion in cash and investments and $238.9 million in revenue, driven by a collaboration with Astellas. The company highlighted strong progress in its hepatitis delta program, with promising clinical trial results for elebsiran and tobevibart, and advanced its oncology pipeline, including the VIR-5500 T-cell engager. VIR projects sufficient capital into the second half of 2028 and anticipates key data readouts for its ECLIPSE studies in late 2026 and early 2027.
Vir Biotechnology (VIR) director restructures 16,000-share holding with Alta Partners fund
Vir Biotechnology, Inc. director Robert J. More reported internal share transfers totaling 16,000 shares of common stock, executed on August 11, 2026. These transactions involved transferring shares held for Alta Partners NextGen Fund I, L.P. (APNG 1) for no consideration in connection with the vesting of restricted stock unit awards. Following these transfers, More directly holds 40,656 shares and indirectly holds 517,917 shares through APNG 1, while disclaiming beneficial ownership of the indirect holdings except for his pecuniary interest.
Vir Biotechnology: Astellas Deal Pushes Cash Above $1 Billion And Extends Runway Into Second Half Of 2028
Vir Biotechnology's cash reserves exceeded $1 billion in Q2 2026, extending its operational runway into late 2028, primarily due to a strategic collaboration with Astellas. This deal, involving a $240 million upfront payment and a $75 million equity investment, focuses on VIR-5500 for prostate cancer, with pivotal Phase 3 trials anticipated to begin in 2027. The company also reported significant progress in its chronic hepatitis delta program, with Phase 3 enrollment complete and topline data expected soon.
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages
Vir Biotechnology, Inc. (NASDAQ:VIR) has an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $20.63, significantly higher than its current price of $8.89. The company recently reported strong quarterly earnings, beating revenue and EPS estimates, despite a negative net margin. Insider activity includes a director selling shares, while institutional investors hold a substantial portion of the company's stock.
Vir Biotechnology (VIR): State Street discloses 9.96M-share, 5.9% ownership position
State Street Corporation, through its investment management subsidiaries, has disclosed a beneficial ownership of 9,964,151 shares of Vir Biotechnology, Inc. common stock, which represents 5.9% of the class as of June 30, 2026. The filing indicates that all voting and dispositive authority is held on a shared basis among its affiliated investment advisers. This disclosure was made via a SCHEDULE 13G form, which is used for passive investment reporting.
What Vir Biotechnology (VIR)'s Profit Swing But Earnings Miss Means For Shareholders
Vir Biotechnology (VIR) reported a significant swing to profitability in Q2 2026, with US$80.08 million in net income and sharply increased revenue of US$238.95 million. Despite this improvement, the company missed analyst expectations for both earnings and sales. The article discusses how this mixed performance, alongside strategic collaborations like the Astellas partnership, shapes Vir Biotechnology's investment outlook, emphasizing clinical execution and commercialization as key catalysts.
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Vir Biotechnology (NASDAQ:VIR) from a "sell" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with a $20.62 target price. The company recently reported strong quarterly earnings, beating EPS and revenue estimates significantly, with revenue soaring by 19582.5% year-over-year. Institutional investors hold a substantial portion of the company, while insider activity showed a director selling a portion of her shares.
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21, Implies 140% Upside
Analysts have slightly lowered the average 12-month price target for Vir Biotechnology, Inc. (VIR) stock from $21.11 to $21, with individual forecasts ranging from $15 to $30. This updated target suggests a potential upside of approximately 140% based on the August 6 closing price. Despite the target adjustment, the consensus rating from 10 analysts remains a "Buy."
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Vir Biotechnology reported its second-quarter 2026 financial results, highlighting strong progress in its clinical programs for chronic hepatitis delta (CHD) and solid tumors. Key updates include promising Phase 2 SOLSTICE data for elebsiran and tobevibart in CHD, with Phase 3 ECLIPSE 1 trial data expected in Q4 2026, and the initiation of dose-expansion cohorts for VIR-5500 in prostate cancer following a collaboration with Astellas. The company ended the quarter with over $1 billion in cash, cash equivalents, and investments, with a net income of $80.1 million.
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21.33, Implies 134% Upside
The average 12-month price target for Vir Biotechnology, Inc. (VIR) stock has been lowered by analysts from $21.56 to $21.11, with individual forecasts ranging from $16 to $30 per share. This updated target suggests a potential upside of approximately 132% based on the August 5th closing price. Despite the target cut, the consensus rating from 10 analysts remains a "Buy," with no "Hold" or "Sell" recommendations.
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Vir Biotechnology, Inc. (VIR) reported Q2 earnings of $0.47 per share, significantly missing the Zacks Consensus Estimate of $0.83, though it represents an improvement from a loss of $0.8 per share a year ago. The company also missed revenue estimates, posting $238.95 million against an expectation of $258.38 million. Despite these misses, VIR shares have seen a 52.1% gain year-to-date, outperforming the S&P 500.
Earnings call transcript: Vir Biotechnology jumps on q2 2026 cash and data gains
Vir Biotechnology reported strong Q2 2026 results, with net income of $80.1 million and cash reserves exceeding $1 billion, largely due to a collaboration payment from Astellas. The company's stock jumped over 10% after hours as investors reacted positively to the improved financial standing, promising hepatitis delta clinical data, and clear upcoming clinical milestones. Vir is advancing its hepatitis delta program with Phase III data expected later this year and early next, alongside progress in its oncology pipeline through the PRO-XTEN platform.
Vir Biotechnology (VIR) Releases Q2 2026 Earnings: Revenue and EPS Beat Estimates
Vir Biotechnology (VIR) reported strong Q2 2026 earnings, exceeding Wall Street estimates with $238.9 million in revenue and $0.47 diluted EPS. The company also demonstrated robust cash generation and ended the quarter with substantial cash and cash equivalents. Insider trading data shows significant sales activity, while institutional holdings indicate both additions and removals of VIR stock by hedge funds, and multiple analysts have issued price targets with a median of $20.5.
Vir Biotechnology Inc. (VIR) Tops Q2 EPS by 14c
Vir Biotechnology Inc. (VIR) surpassed analyst expectations for its second-quarter earnings, reporting an EPS of $0.47, which was $0.14 higher than the estimated $0.33. The company also significantly beat revenue forecasts, achieving $238.94 million against a consensus estimate of $135.88 million.
Vir Biotechnology (NASDAQ: VIR) swings to profit on $239.3M Astellas deal
Vir Biotechnology reported a substantial swing to profit in Q2 2026, driven by a $239.3 million licensing and collaboration revenue from its VIR-5500 deal with Astellas. The company posted a net income of $80,080 thousand, a significant improvement from a net loss of $110,958 thousand in the prior year, bringing its cash, cash equivalents, and investments to approximately $1.01 billion. Despite this profitable quarter, the company recorded a net loss of $45,615 thousand for the six months ended June 30, 2026, as it continues to heavily invest in its infectious disease and oncology pipeline, including advancing its ECLIPSE registrational program for hepatitis delta.
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21.11, Implies 132% Upside
The average 12-month price target for Vir Biotechnology, Inc. (VIR) stock has been lowered slightly from $21.56 to $21.11 by 9 analysts, with individual forecasts ranging from $16 to $30. This new target suggests a potential upside of approximately 132% based on the August 5th closing price. The consensus analyst rating remains a "Buy" from all 10 covering analysts.
Investors brace for Vir Biotech earnings amid turnaround bid By Investing.com
Vir Biotechnology Inc. is preparing to report second-quarter earnings, with analysts expecting a significant turnaround after a challenging first quarter. The company faces scrutiny regarding its revenue forecast, the progress of its hepatitis B pipeline, and a recent CFO transition. Investors are looking for signs of consistent financial performance to justify the bullish outlook.
Renaissance Technologies LLC Increases Stake in Vir Biotechnology, Inc. $VIR
Renaissance Technologies LLC significantly increased its stake in Vir Biotechnology, Inc. by 23.9% in the first quarter, now owning 761,364 shares valued at $6.8 million. Other institutional investors also raised their holdings, contributing to institutions collectively owning 65.32% of the company. Despite a recent quarterly loss and missed earnings estimates, analysts generally maintain a "Moderate Buy" rating with a consensus target price of $20.88 for Vir Biotechnology.
Public Employees Retirement System of Ohio Acquires Shares of 112,700 Vir Biotechnology, Inc. $VIR
The Public Employees Retirement System of Ohio recently acquired 112,700 shares of Vir Biotechnology, Inc. (NASDAQ:VIR), valued at approximately $1.01 million, establishing a 0.07% stake in the company. Institutional investors now collectively own 65.32% of Vir Biotechnology, which has an average analyst rating of "Moderate Buy" despite reporting a significant quarterly loss and negligible revenue. Insider activity also noted a director selling 3,200 shares for $30,240.
Vir Biotechnology Inc expected to post earnings of 33 cents a share - Earnings Preview
Vir Biotechnology Inc (VIR) is projected to report earnings of 33 cents per share. This financial outlook is based on an earnings preview from Refinitiv, providing insight into the company's expected performance.
950,000 Shares in Vir Biotechnology, Inc. $VIR Bought by Avidity Partners Management LP
Avidity Partners Management LP recently acquired 950,000 shares of Vir Biotechnology, Inc. (NASDAQ:VIR) valued at approximately $8.5 million, making it their 12th largest position and representing 0.56% of the company. Despite institutional ownership of 65.32%, Vir Biotechnology's stock opened lower, and the company reported a significant quarterly loss and revenue miss. Analysts maintain a "Moderate Buy" consensus with a target price of $20.88, although some have downgraded the stock.
Vanguard Portfolio Management (VIR) discloses 11.6M-share Vir Biotechnology position
Vanguard Portfolio Management has disclosed a beneficial ownership of 11,554,377 shares of Vir Biotechnology Inc. common stock, representing 6.85% of the class as of June 30, 2026. This information was reported on an amended Schedule 13G filing. Vanguard holds sole voting power over 59,162 shares and sole dispositive power over all 11,554,377 shares, on behalf of its affiliated entities and managed accounts.
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Report - Results, Call & Slides
Vir Biotechnology (VIR) reported its Q1 2026 earnings, missing both EPS and revenue expectations significantly. Despite the financial misses, the company highlighted substantial positive developments including a strategic collaboration with Astellas valued up to $1.7 billion, material capital raises, strong early clinical data for VIR-5500, and compelling Phase 2 results for its Hepatitis Delta program, leading management to project a cash runway into 2028.
SB Investment Advisers UK Ltd. Sells 2,168,884 Shares of Vir Biotechnology, Inc. $VIR
SB Investment Advisers UK Ltd. significantly reduced its stake in Vir Biotechnology (NASDAQ:VIR) by selling over 2.1 million shares in Q1 2026, though it remains a top holding. This comes amidst a substantial quarterly earnings miss for Vir Biotechnology and mixed analyst ratings, with a "Moderate Buy" consensus and a price target well above its current trading price. Insider selling has also been reported, while institutional investors collectively own 65.32% of the company's stock.
ADAR1 Capital Management LLC Invests $24.59 Million in Vir Biotechnology, Inc. $VIR
ADAR1 Capital Management LLC has recently invested $24.59 million in Vir Biotechnology, Inc. (NASDAQ:VIR), acquiring over 2.7 million shares, making it their 14th largest portfolio position. Other institutional investors like Pictet Asset Management Holding SA and Candriam S.C.A. have also increased their stakes. The article also details recent insider stock sales, the company's financial performance, and current analyst ratings, which suggest a "Moderate Buy" consensus.
VIR|Vir Biotechnology Inc|Price:8.655|Chg%:-0.196
This report provides a comprehensive analysis of Vir Biotechnology Inc (VIR), focusing on its stock score, financial health, valuation, and market performance. TradingKey assesses the company's fundamentals as healthy with significant growth potential, despite a weak stock market performance recently. The stock is considered fairly valued, ranks well within its industry, and shows high institutional ownership and analyst confidence, with a target price indicating substantial upside.
Eversept Partners LP Takes $2.24 Million Position in Vir Biotechnology, Inc. $VIR
Eversept Partners LP has acquired a new position in Vir Biotechnology, Inc. (NASDAQ:VIR), purchasing 250,000 shares valued at $2.24 million, representing 0.15% of the company. Institutional investors collectively own 65.32% of Vir's stock, though several insiders have recently sold shares. Despite a significant earnings miss and negative profitability, analysts have a "Moderate Buy" consensus rating with an average price target of $20.88.
Empyrean Capital Partners LP Invests $4.73 Million in Vir Biotechnology, Inc. $VIR
Empyrean Capital Partners LP has purchased a new stake of 527,800 shares in Vir Biotechnology, Inc. (NASDAQ:VIR) during the first quarter, valued at approximately $4.73 million. This makes Empyrean Capital Partners LP own about 0.31% of the company's stock. Other institutional investors like GSK plc and Pictet Asset Management Holding SA also adjusted their positions in Vir Biotechnology, while company insiders made recent sales.
Vir Biotechnology Names Brent Sabatini Interim Finance Chief
Vir Biotechnology announced that its Executive Vice President and CFO, Jason O’Byrne, will step down on August 3, 2026. The company has appointed Brent Sabatini, Senior Vice President and Chief Accounting Officer, as interim principal financial officer, effective the same date. Vir Biotechnology is actively searching for a permanent successor and emphasizes that O'Byrne's departure is not due to any disagreements over operations or practices, ensuring a smooth leadership transition.
Vir Biotechnology, Inc. Revenue Breakdown – NASDAQ:VIR
Vir Biotechnology, Inc. (NASDAQ: VIR) reported its revenue breakdown. In the last fiscal year, the company generated $68.56 million USD, with its Antibody-based Therapies segment being the top-performing contributor. The United States was the largest regional contributor to this revenue.
Vir Biotechnology Appoints Interim CFO Amid Transition
Vir Biotechnology has appointed Brent Sabatini as interim Principal Financial Officer, effective July 23, following Jason O’Byrne's departure on August 3. Sabatini, previously Senior Vice President and Chief Accounting Officer, brings over two decades of financial experience. The company anticipates a Phase III trial for VIR-5500 in 2027 and expects its cash runway to extend into the second half of 2028, despite reporting a GAAP EPS of -$0.85.
Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings Report - Results, Call & Slides
Vir Biotechnology, Inc. (VIR) reported its Q4 2023 earnings, beating analyst expectations with an actual EPS of -$15.06 against a consensus of -$17.65 and actual revenue of $293.92M against an expected $195.66M. Despite the revenue beat, there was a significant year-over-year revenue growth decrease of -66.03%. The company announced its next estimated earnings date for August 5, 2026.
Vir Biotechnology Names Brent Sabatini Interim Finance Chief
Vir Biotechnology announced that its Executive Vice President and CFO, Jason O’Byrne, will step down on August 3, 2026, for another opportunity unrelated to company disagreements. Brent Sabatini, Senior Vice President and Chief Accounting Officer, will serve as interim principal financial officer starting the same day, to ensure financial continuity during the search for a permanent successor. A recent analyst rating on VIR stock is a Buy with a $27.00 price target, though TipRanks’ AI Analyst, Spark, rates VIR as Neutral due to strong catalysts offset by weak financial performance.
Why is Vir Biotechnology stock sliding today?
Vir Biotechnology stock dropped over 7% after the company announced the resignation of its CFO, Jason O’Byrne, just days before its next earnings report. This executive departure, coupled with a previous CMO exit and a weak market for growth stocks, has amplified investor concerns about organizational stability. Brent Sabatini has been appointed as Interim Principal Financial Officer while the company searches for a permanent successor.
VIR|Vir Biotechnology Inc|Price:8.675|Chg%:-0.665
This article provides a comprehensive overview of Vir Biotechnology Inc. (VIR), detailing its stock performance, key financial figures, and a TradingKey stock score. It highlights the company's strong fundamentals, growth potential, and "Buy" rating from analysts, despite recent stock market underperformance. The article also outlines Vir Biotechnology's focus on developing medicines for infectious diseases and cancer, along with its specific pipeline products.
Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer
Vir Biotechnology has appointed Brent Sabatini as Interim Principal Financial Officer, effective immediately. Sabatini, who joined Vir in 2023, will be responsible for overseeing the company's financial operations while Vir searches for a permanent Chief Financial Officer. He brings extensive experience in biotech finance and strategy to the role.
Vir Biotechnology Announces Chief Financial Officer Transition
Vir Biotechnology announced that Brent Sabatini has been appointed Interim Principal Financial Officer, effective July 23, 2026. This transition follows Jason O’Byrne's departure to pursue another opportunity, though he will remain with the company until August 3 to ensure a smooth handover. The company has initiated a comprehensive search for a permanent Chief Financial Officer.
Vir Biotechnology Appoints Brent Sabatini as Interim CFO Following Jason O'Byrne's Resignation
Vir Biotechnology announced that Jason O'Byrne will step down as Executive Vice President and Chief Financial Officer, effective August 3, 2026, to pursue another opportunity. Brent Sabatini, CPA, MBA, Senior Vice President and Chief Accounting Officer, has been appointed as the interim principal financial officer, starting the same date. Sabatini brings over two decades of finance and accounting experience to this interim role.
Vir Biotechnology (VIR) Appoints Interim Financial Officer Amid Leadership Changes
Vir Biotechnology Inc. (VIR) has appointed Brent Sabatini as interim Principal Financial Officer, effective July 23, 2026, following Jason O’Byrne's departure. Sabatini, who was previously Senior Vice President and Chief Accounting Officer, brings over 20 years of financial experience. The company, which has a market capitalization of $1.58 billion and a GF Score™ of 51/100, is navigating financial challenges and has seen recent insider selling of $0.3 million.
Vir Biotechnology names interim finance chief
Vir Biotechnology, Inc. has appointed Brent Sabatini as its Interim Principal Financial Officer, effective Wednesday. Sabatini, who was previously Senior Vice President and Chief Accounting Officer, replaces Jason O’Byrne, who is leaving the company. Vir Biotechnology has initiated a search for a permanent CFO.
Vir Biotechnology, Inc. Announces Resignation of Jason O'Byrne as Executive Vice President, Effective August 3, 2026
Vir Biotechnology, Inc. announced that Jason O'Byrne, MBA, Executive Vice President and Chief Financial Officer, will resign from his role effective August 3, 2026, to pursue another opportunity. The company clarified that his resignation was not due to any disagreements regarding operations, policies, or practices. Vir Bio has initiated a search for his successor.
Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer
Vir Biotechnology Inc. has appointed Brent Sabatini, its Senior Vice President and Chief Accounting Officer, as Interim Principal Financial Officer. This appointment follows Jason O’Byrne's departure to pursue another opportunity. The company has launched a search for a new Chief Financial Officer, with CEO Marianne De Backer expressing confidence in Sabatini's financial acumen during this transition.
Vir Biotechnology Announces Chief Financial Officer Transition
Vir Biotechnology, Inc. announced that Brent Sabatini has been appointed Interim Principal Financial Officer, effective July 23, following Jason O’Byrne's departure. The company is initiating a comprehensive search for a new Chief Financial Officer. CEO Marianne De Backer expressed confidence in Sabatini, highlighting his deep institutional knowledge and financial acumen.
VIR Q2'26 Earnings: revenue estimate is 135.88M USD
Vir Biotechnology, Inc. (VIR) is scheduled to release its Q2'26 earnings on July 30, 2026. Analysts project a revenue of $135.88 million and diluted earnings per share (EPS) of $0.33
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR) announced it will host a conference call on Wednesday, August 5, 2026, at 4:30 p.m. ET / 1:30 p.m. PT. The call will provide a corporate update and discuss financial results for the second quarter ended June 30, 2026. Interested parties can access the call details on the Events & Presentations page of the company's website.
Vir Biotechnology to host conference call for Q2 2026 results
Vir Biotechnology announced it will host a conference call on August 5, 2026, at 4:30 p.m. ET to discuss its second-quarter financial results and provide a corporate update. The company, a clinical-stage biopharmaceutical firm, focuses on developing treatments for infectious diseases and cancer, leveraging its PRO-XTEN® masking platform. The call will be accessible via their website's Events & Presentations section.
